Vical expands CMV vaccines portfolio
San Diego, USA-based Vical has announced a license agreement with The Wistar Institute granting it exclusive, worldwide rights to the latter's Towne strain of cytomegalovirus and related technologies. Financial terms of the license agreement were not disclosed.
The Towne strain is an attenuated, or weakened, form of human CMV which was developed for potential vaccine applications by renowned vaccinologist Stanley Plotkin, a member of Wistar's research faculty from 1960 to 1991 and co-author of the definitive medical text Vaccines. Dr Plotkin is currently executive advisor to Sanofi Pasteur, the vaccine division of French drug major Sanofi-Aventis, professor emeritus of virology at The Wistar Institute, and professor emeritus of pediatrics at the University of Pennsylvania. Among his many contributions to vaccine research while at Wistar, he developed the Rubella vaccine now in common use worldwide, as well as experimental vaccines against polio and varicella and collaborated on vaccines against rabies and rotavirus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze